Table 1.
List of included studies with their individual features
| Author/year | Trial/type of study | Ethnicity | No. pts | CPS ≥10/PD-L1 ≥1 | Line of therapy | Histology | Median follow-up (months) | Arms | ORR (%) | PFS (HR, 95%CI) | OS (HR, 95%CI) | Risk of bias |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun/2021 | KEYNOTE590/randomized | Asian and non | 373 versus 376 | 143 versus 143b/NA | 1st | ESCC & ADK | PEMBRO + CT versus CT alone | — | 0.65 (0.54-0.78)b | 0.72 (0.60-0.88)b | Low | |
| Kojima/2020 | KEYNOTE181/randomized | Asian and non | 314 versus 314 | 85 versus 82b/NA | 2nd | ESCC & ADK | PEMBRO versus CT (investigator's choice) | 16.7 versus 7.4b | 0.92 (0.75-1.13)b | 0.75 (0.61-0.93)b | Low | |
| Kato/2019 | ATTRACTION3/randomized | Asian and non | 210 versus 209 | NA/101 versus 102e | 2nd | ESCC | NIVO versus CT (investigator's choice) | 19 versus 22 | 1.08 (0.87-1.34) | 0.77 (0.62-0.96) | Low | |
| Chau/2021 | CHECKMATE648a/randomized | Asian and non | 321 versus 325 versus 324 | NA/158 versus 158 versus 157e | 1st | ESCC | NIVO + CT versus NIVO + IPI versus CT alone | 47 versus 27c 28 versus 27d |
0.81 (0.64-1.04)c 1.26 (1.04-1.52)d |
0.74 (0.58-0.96)c 0.78 (0.62-0.98)d |
Moderate | |
| Shen/2021 | ORIENT15a/randomized | Asian | 327 versus 332 | 188 versus 193/NA | 1st | ESCC | Sintilimab + CT versus CT alone | 66.1 versus 45.5 | 0.55 (0.46-0.67) | 0.62 (0.50-0.77) | Moderate | |
| Xu/2021 | JUPITER06a/randomized | Asian | 257 versus 257 | 115 versus 97/201 versus 200f | 1st | ESCC | Toripalimab + CT versus CT alone | — | 0.58 (0.46-0.74) | 0.58 (0.43-0.78) | Moderate | |
| Huang/2020 | ESCORT/randomized | Asian | 228 versus 220 | NA/26 versus 35e | 2nd | ESCC | Camrelizumab versus CT | 20.2 versus 6.4 | 0.69 (0.56-0.86) | 0.71 (0.57-0.88) | Low | |
| Shen/2021 | RATIONALE302a/randomized | Asian and non | 256 versus 256 | 89 versus 68/NA | 2nd | ESCC | Tislelizumab versus CT | 20.3 versus 9.8 | 0.83 (0.67-1.01) | 0.70 (0.57-0.85) | Moderate | |
| Luo/2021 | ESCORT-1st/randomized | Asian | 298 versus 298 | NA/104 versus 98e | 1st | ESCC | Camrelizumab + CT versus CT alone | 72.1 versus 62.1 | 0.56 (0.46-0.68) | 0.70 (0.56-0.88) | Low | |
| Xu/2020 | ORIENT2a/randomized | Asian | 95 versus 95 | — | 2nd | ESCC | Sintilimab versus CT | 12.6 versus 6.3 | 1.00 (0.77-1.39) | 0.70 (0.50-0.97) | Moderate |
ADK, adenocarcinoma; CI, confidence interval; CPS, combined positive score; CT, chemotherapy; ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; IPI, ipilimumab; NA, not applicable; NIVO, nivolumab; ORR, overall response rate; OS, overall survival; PD-L1, programmed death-ligand 1; PEMBRO, pembrolizumab; PFS, progression-free survival.
a
Abstract.
b
ESCC group.
c
NIVO + CT versus CT.
d
NIVO + IPI versus CT.
e
Tumor proportion score.
f
CPS.